Noul Presents at Korea’s Largest Biotech Investment Conference, KBIC 2019

Noul Co., Ltd. (Noul) introduced its breakthrough Next Generation Immunoassay and Staining (NGS™I) technology and their diagnostics platform, miLab™ at Korea’s largest biotech investment conference, Korea Bio Investment Conference (KBIC) on August 28th to 29th. 

2019 Korea Bio Investment Conference (KBIC) was co-hosted by Korea Biotechnology Industry Organization (한국 바이오 협회) and Korea Economic Daily (한국경제신문사) to an audience of estimated 1,000 investors, fund managers, analysts, and VCs in biotech and pharmaceutical industries. 50 rising-star start-ups and corporations in the Korean bio and healthcare industries were selected to present at the exhibition to industry’s most influential guests and media attendees. 

 
IMG_2015.JPG
 

Noul’s co-founder and CEO David Lim introduced Noul’s breakthrough technology NGSI™ (Next Generation Staining and Immunoassay) and its main diagnostics platform, miLab™. The miLab™ diagnostic platform automates the workflow of a traditional manual microscopy test performed by a clinical laboratory - from sample slide-preparation to image review and diagnosis. miLab™ combines gold standard morphology-based diagnosis workflow into a fully automated and scalable point-of-care platform for small to medium-size laboratories and local clinics.

“We have updated the manual microscopy process that has been the gold standard for the past 100 years” said David Lim, CEO of Noul. “miLab™ empowers medical facilities with limited resources to conduct morphology-based confirmed diagnosis without large scale commitment for equipment, infrastructure, and skilled experts required in a traditional clinical laboratory setting.” 

Noul is targeting a 1H 2020 release of the miLab™ diagnostics platform.

Noul Co., Ltd.